Bondronat
·
- Prescription status not stated
- Muscles, joints and bones
- Active substance
- Ibandronic acid
- Used in
- Muscles, joints and bones
- Made by
- Atnahs Pharma Netherlands B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Bondronat is indicated for: prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases; treatment of tumour-induced hypercalcaemia with or without metastases.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
BulgariaNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Atnahs Pharma Netherlands B.V. |
|---|---|
| Active substance | Ibandronic acid |
| Used in | Muscles, joints and bones |
| Classification | M05BA06 · Muscles, joints and bones |
| Authorised on | 1996-06-25 |
| Last updated by the regulator | 2024-09-16 |
| EMA product number | EMEA/H/C/000101 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.